Whalesbook
Generic Giants Target ₹5000 Crore Semaglutide Opportunity
At least fifteen Indian pharmaceutical companies are gearing up to capture an estimated ₹5,000 crore market opportunity arising from the patent expiry of semaglutide, a key ingredient in blockbuster diabetes and weight-loss drugs. This surge in interest follows the impending patent expiration in India and emerging markets in March 2026, though experts caution that the path to international markets is heavily constrained by regulatory complexities.
Global Aspirations, Local Realities
Systematix Group projects an incremental revenue opportunity exceeding ₹50 billion (approximately ₹5,000 crore) over the next 12 to 15 months for generic versions of semaglutide. While India and emerging markets offer a more accessible entry point, developed markets like Canada and Brazil present significant challenges. "In regulated developed markets, approvals generally take more time, and they are cautious about approving peptides," noted Vishal Manchanda, Senior Vice-President (Institutional Research) at Systematix Group. Historically, few peptide generics have found success in these regions.
Navigating Regulatory Mazes
Semaglutide, a GLP-1 analogue developed by Novo Nordisk, is the active component in popular medications such as Wegovy, Ozempic, and Rybelsus. Companies are already making strategic moves. Dr. Reddy's Laboratories, an early entrant, secured a December 2025 Delhi High Court ruling permitting exports to countries without patent protection on the drug. However, the company is still awaiting crucial regulatory approval to sell in Canada. Sun Pharma made a similar commitment to the Delhi High Court, agreeing not to launch in India until Novo Nordisk's patent expires but gaining permission to manufacture and export.
Patent Battles and Market Projections
Intellectual property expert Rajeshwarie Hariharan clarified that current export permissions are primarily for seeking regulatory approvals, not for large-scale commercial sales. In a significant development on December 31, 2025, Novo Nordisk announced that China's Supreme People's Court upheld its intellectual property rights concerning the semaglutide compound patent. Despite this, the Danish firm maintained its earlier assessment that the patent expiry in certain countries would only have a minor, low-single-digit negative impact on global sales growth in 2026.
Systematix forecasts robust revenue streams: ₹1,000-2,000 crore from India's branded formulation market, a substantial ₹4,500 crore from regulated markets like Canada and Brazil, and ₹500-1,000 crore from emerging markets for FY27E. While the immediate opportunity in regulated markets might be large, it is expected to diminish over time due to significant regulatory and commercial risks. Conversely, opportunities in India and emerging markets may develop more slowly but offer greater long-term expansion potential with lower regulatory barriers.